Search

Patient initiated follow-up in head and neck cancer

Is it time for a change in the way we follow up head and neck cancer patients after treatment? Paul Nankivell and Hisham Mehanna explain the rationale for the PETNECK2 trial. After completion of curative intent treatment, clinical follow-up currently...

Detecting cancer margins during robotic head and neck cancer surgery using ambient mass spectrometry

We have known about altered metabolism in cancer cells since Otto Warburg described it 97 years ago. But can we take advantage of this knowledge in curing cancer? Jim Higginson explains the value of smoke generated during cancer surgery. The...

Head and neck robotic surgery – considerations for the surgical trainee

In 2021, training in head and neck cancer surgery would be incomplete without some robotic resections under the belt. Henry Zhang explains how he did it and outlines the options available. With a wide range of applications in both benign...

Aerosol research and performance

Is singing safe? This was a question asked around the world at the start of the pandemic in early 2020. Natalie Watson and Chris Orton tell us about a rapidly-convened research group that led to profound changes in UK Government...

Rapid genetic testing to avoid hearing loss in neonates

Thousands of newborn babies could avoid a lifetime of hearing loss thanks to a new rapid genetic test. In this article, we learn how. We have demonstrated for the first time that a rapid genetic test from a cheek swab...

Aligning hearing and cognitive healthcare in older people

Published in print under the titleHearing care and dementia: professional insights on the new Lancet Commission findingsThe Lancet Commission on ‘Dementia prevention, intervention and care: 2024 report’ highlights a list of potential modifiable factors to reduce dementia risk. As with...

Temporal bone trauma

Introduction Temporal bone injuries represent one of the more complex management problems presenting to the otolaryngologist. This is largely due to difficulties in assessment and the frequent delays in referral, often as a result of other injuries demanding more immediate...

Systemic agents in thyroid cancer

For those patients who have disseminated or unresectable thyroid cancer, Dr Arabella Hunt and Dr Kate Newbold review systemic treatments, their differences, toxicities and outcomes. Thyroid cancer is the most common endocrine malignancy. It is subdivided into differentiated (papillary, follicular...